New Novartis data show early addition of twice-yearly*

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal...

Related Keywords

United States ,South Korea ,China ,Switzerland ,Netherlands ,Amsterdam ,Noord Holland ,Japan ,America ,Swiss ,Han ,American ,Jonathan Graham ,Richard Jarvis ,Isabella Zinck ,Satoshi Sugimoto ,Nicole Zinsli Somm ,Coll Cardiol ,Parag Mahanti ,Michael Meo ,Imke Kappes ,Michael Koren ,Marlena Abdinoor ,Sloan Simpson ,American Heart Association ,Novartis Pharmaceuticals Corp ,American College Of Cardiology Congress ,Instagram ,Alnylam Pharmaceuticals ,European Society Of Cardiology Congress ,World Health Organization ,European Union ,Jacksonville Center ,Journal Of The American College Cardiology ,Linkedin ,Exchange Commission ,European Medicines Agency ,Facebook ,World Heart Federation ,American College Of Cardiology Heart Association ,Clinical Research ,Public Health ,National Medical Products Administration ,Novartis ,Health Promotion Series ,Annual Scientific Session ,American College ,Medical Director ,Atherosclerotic Cardiovascular Disease ,Cardiology Congress ,European Society ,Medical Products ,Pharmaceuticals Corp ,American Heart ,American Heart Association Task Force ,Clinical Practice ,World Heart ,Published May ,Swiss Stock Exchange Novn ,Novartis Pharma Ag ,Media Release ,Reimagine Medicine ,Medical Innovations ,